Botanix reaches term sheet agreement with 2nd API supplier
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Botanix Pharmaceuticals Limited has reached a term sheet agreement with PPL Pharma Solutions Riverview LLC for a manufacturing and supply arrangement. This agreement will allow Piramal to serve as an alternate commercial supplier of Sofpironium Bromide, the active ingredient in Sofdra®. The arrangement is expected to reduce the cost of goods sold and enhance gross profit for Botanix.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Successful renegotiation of API supply agreement
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D and Half Year Report
- Botanix Receives Capital Raise Commitments of A$45 Million
- Trading Halt
Later from Botanix Pharmaceuticals
- Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
- Intention to Grant a European patent on Sofdra applicator
- Notice of Allowance for US patent on Sofdra drug substance
- Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
- Appendix 4E & Annual Report for the Year Ended 30 June 2026
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals